<?xml version='1.0' encoding='utf-8'?>
<document id="21440623"><sentence text="In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate."><entity charOffset="99-111" id="DDI-PubMed.21440623.s1.e0" text="methotrexate" /></sentence><sentence text="Methotrexate is the most commonly used drug to treat rheumatoid arthritis"><entity charOffset="0-12" id="DDI-PubMed.21440623.s2.e0" text="Methotrexate" /></sentence><sentence text=" Since clinical efficacy studies in rheumatoid arthritis are conducted on a background of methotrexate therapy, it is necessary to assess the potential of rheumatoid arthritis candidate drugs to perpetrate a drug-drug interaction (DDI) with methotrexate during development"><entity charOffset="90-102" id="DDI-PubMed.21440623.s3.e0" text="methotrexate" /><entity charOffset="241-253" id="DDI-PubMed.21440623.s3.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.21440623.s3.e0" e2="DDI-PubMed.21440623.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21440623.s3.e0" e2="DDI-PubMed.21440623.s3.e1" /></sentence><sentence text=" Consequently, we need to identify the regulatory in vitro studies required to facilitate this assessment" /><sentence text=" We therefore reviewed the literature to ascertain the methotrexate disposition pathways implicated with known DDIs"><entity charOffset="55-67" id="DDI-PubMed.21440623.s5.e0" text="methotrexate" /></sentence><sentence text=" Experiments were conducted to confirm that methotrexate was identified as a substrate for these pathways in our laboratory"><entity charOffset="44-56" id="DDI-PubMed.21440623.s6.e0" text="methotrexate" /></sentence><sentence text=" The literature indicated active renal elimination (mediated by the human transporters OAT1, OAT3, MRP2 and BCRP) to be the principal pathway for methotrexate DDI risk"><entity charOffset="146-158" id="DDI-PubMed.21440623.s7.e0" text="methotrexate" /></sentence><sentence text=" With the exception of MRP2, methotrexate was confirmed as a substrate of these transporters using oocyte and membrane vesicle test systems"><entity charOffset="29-41" id="DDI-PubMed.21440623.s8.e0" text="methotrexate" /></sentence><sentence text=" A rheumatoid arthritis candidate drug (AZD9056) and sulfasalazine were subsequently assessed as inhibitors of OAT1, OAT3 and BCRP to determine their DDI potential towards methotrexate"><entity charOffset="53-66" id="DDI-PubMed.21440623.s9.e0" text="sulfasalazine" /><entity charOffset="172-184" id="DDI-PubMed.21440623.s9.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.21440623.s9.e0" e2="DDI-PubMed.21440623.s9.e0" /><pair ddi="false" e1="DDI-PubMed.21440623.s9.e0" e2="DDI-PubMed.21440623.s9.e1" /></sentence><sentence text=" AZD9056 was neither an inhibitor of OAT1 nor OAT3 and did not inhibit their transport of methotrexate"><entity charOffset="1-8" id="DDI-PubMed.21440623.s10.e0" text="AZD9056" /><entity charOffset="90-102" id="DDI-PubMed.21440623.s10.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.21440623.s10.e0" e2="DDI-PubMed.21440623.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21440623.s10.e0" e2="DDI-PubMed.21440623.s10.e1" /></sentence><sentence text=" AZD9056 was an inhibitor of BCRP and weakly inhibited BCRP-mediated transport of methotrexate (IC(50)=92μM)"><entity charOffset="1-8" id="DDI-PubMed.21440623.s11.e0" text="AZD9056" /><entity charOffset="82-94" id="DDI-PubMed.21440623.s11.e1" text="methotrexate" /><entity charOffset="96-107" id="DDI-PubMed.21440623.s11.e2" text="IC(50)=92μM" /><pair ddi="false" e1="DDI-PubMed.21440623.s11.e0" e2="DDI-PubMed.21440623.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21440623.s11.e0" e2="DDI-PubMed.21440623.s11.e1" /><pair ddi="false" e1="DDI-PubMed.21440623.s11.e0" e2="DDI-PubMed.21440623.s11.e2" /><pair ddi="false" e1="DDI-PubMed.21440623.s11.e1" e2="DDI-PubMed.21440623.s11.e1" /><pair ddi="false" e1="DDI-PubMed.21440623.s11.e1" e2="DDI-PubMed.21440623.s11.e2" /></sentence><sentence text=" Sulfasalazine inhibited methotrexate transport mediated by all transporters studied (IC(50)&lt;5μM)"><entity charOffset="1-14" id="DDI-PubMed.21440623.s12.e0" text="Sulfasalazine" /><entity charOffset="25-37" id="DDI-PubMed.21440623.s12.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.21440623.s12.e0" e2="DDI-PubMed.21440623.s12.e0" /><pair ddi="false" e1="DDI-PubMed.21440623.s12.e0" e2="DDI-PubMed.21440623.s12.e1" /></sentence><sentence text=" Subsequent assessment of the in vitro data using [I]/IC(50) ratios indicated that both AZD9056 and sulfasalazine were unlikely to cause a DDI with methotrexate in vivo"><entity charOffset="88-95" id="DDI-PubMed.21440623.s13.e0" text="AZD9056" /><entity charOffset="100-113" id="DDI-PubMed.21440623.s13.e1" text="sulfasalazine" /><entity charOffset="148-160" id="DDI-PubMed.21440623.s13.e2" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.21440623.s13.e0" e2="DDI-PubMed.21440623.s13.e0" /><pair ddi="false" e1="DDI-PubMed.21440623.s13.e0" e2="DDI-PubMed.21440623.s13.e1" /><pair ddi="false" e1="DDI-PubMed.21440623.s13.e0" e2="DDI-PubMed.21440623.s13.e2" /><pair ddi="false" e1="DDI-PubMed.21440623.s13.e1" e2="DDI-PubMed.21440623.s13.e1" /><pair ddi="false" e1="DDI-PubMed.21440623.s13.e1" e2="DDI-PubMed.21440623.s13.e2" /></sentence><sentence text=" In conclusion, to support rheumatoid arthritis drug development it is proposed that regulatory in vitro studies for OAT1, OAT3 and BCRP inhibition be routinely conducted to assess the potential for a transporter-mediated DDI with methotrexate in vivo"><entity charOffset="231-243" id="DDI-PubMed.21440623.s14.e0" text="methotrexate" /></sentence><sentence text="" /></document>